Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jazz Pharmaceuticals' (JAZZ) Weak 4Q Results and 2016 Guidance Has Mizuho Securities Sidelined - PT to $124
February 24, 2016 6:54 AM ESTMizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $124.00 (from $140.00), following the company's 4Q earnings report. JAZZ reported revenue of $340.9M and EPS of $2.60 versus consensus estimates of $350.8M and $2.60. Management also issued below-consensus 2016 guidance of... More
Jazz Pharmaceuticals (JAZZ) Reports In-Line Q4 EPS, FY Guidance Comes in Light
February 23, 2016 4:11 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.60, in-line with the analyst estimate of $2.60. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $349.83 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2016 EPS of $10.90-$11.30, versus the consensus of $11.42. Jazz... More
